What Limits Viscosity and Fill Accuracy in Non-Aqueous Pour-On Processing?

The non-aqueous cattle pour-on route imposes a narrow viscosity window because abamectin is delivered as a spreadable dorsal film; if kinematic viscosity exceeds 50 mPa·s at 25°C, drizzle-type dosing guns show intermittency at the 10 mL calibration notch, while below 20 mPa·s the film drains unevenly and increases tail-flick losses. The manufacturing target is a solution containing 0.5% w/v (5 g/L) abamectin calculated as avermectin B1a, with a process overage of 1.0–2.5% w/w to compensate for depth-filter retention and line losses. The API is a fermentation-derived mixture containing not less than 80% avermectin B1a and not more than 20% avermectin B1b, with a needle-like crystal habit that varies between production lots; each lot is pre-sieved through a 180 µm screen before weighing because aggregates otherwise survive the initial solvent contact and reduce assay uniformity.

Compounding runs use a closed stainless-steel vessel with a bottom-entry rotor-stator homogenizer at 1,500–3,000 rpm; the vessel headspace is sparged with nitrogen to 0.2 bar overpressure because residual oxygen drives B1a oxidation. The solution is passed through a 10 µm polypropylene depth filter, and differential pressure is recorded continuously: a rise beyond 0.8 bar before the batch is complete flags residual moisture above 0.3% w/w, which hydrates fine crystals and blinds the medium, producing variable fill-line pressure. Filling is performed on a mass-flow cabinet line calibrated to ±0.5% target fill weight; terminal packages are fluorinated HDPE or co-extruded HDPE/PA in 1 L, 5 L, 10 L, and 20 L formats. Release testing includes viscosity per ISO 2555:2018, density per Ph. Eur. 2.2.5, residual solvents per USP <467> or VICH GL18, photostability under VICH GL3, and long-term stability under VICH GL5. The finished dossier is bound to EU Regulation 2019/6 and the applicable MRL classification under Commission Regulation (EU) No 37/2010 for the target species. Aqueous contamination must remain below 0.2% w/w because crossing that threshold produces a persistent haze that is not cleared by post-filtration agitation and degrades the B1a assay within weeks.

Sterile Injectable Manufacture Under Nitrogen Overlay

The 1.0% w/v (10 mg/mL) injectable solution presents a thermal-stability boundary that excludes terminal steam sterilization; the macrocyclic lactone ring degrades when heated in the presence of trace water and free acid, so the process is built around sterilizing filtration at a bulk temperature not exceeding 40°C. The vehicle consists of glycerol formal and propylene glycol adjusted to a viscosity band of 35–55 mPa·s at 25°C; if the upper limit is exceeded, silicone tubing and filling needle valves produce inconsistent fill volumes, and if the mix falls below 35 mPa·s, the solution wets the stopper shoulder and increases sub-visible particulate counts. Dissolution is conducted in a jacketed vessel under 0.2 bar nitrogen overlay, with headspace oxygen held below 2.0% v/v; the batch is sequentially passed through a 0.45 µm PVDF prefilter and a 0.22 µm PVDF final filter. Differential pressure across the final filter above 1.0 bar is an actionable alarm because it indicates crystal growth or cosmetic precipitate from moisture ingress above 0.2% w/w.

Filling runs use washed and depyrogenated Type II amber glass vials with siliconized chlorobutyl stoppers in volumes of 50 mL, 100 mL, 250 mL, and 500 mL; vial neck flushing with nitrogen reduces stopper extractable oxidation and headspace oxygen. Release panels include sterility per USP <71> or Ph. Eur. 2.6.1 with 14-day incubation, bacterial endotoxins per USP <85> or Ph. Eur. 2.6.14, sub-visible particulates per USP <788> or Ph. Eur. 2.9.19, assay and related substances by HPLC with UV detection at 245 nm, and residual moisture by Ph. Eur. 2.5.12. The manufacturing boundary for this route is water concentration below 0.2% w/w in the bulk solvent; exceedance produces filter blinding, stopper incompatibility, and a fall in B1a assay after 3 months at 40°C/75% RH because hydrolysis products form at the lactone oxygen. Line changeover after the injectable run requires a two-stage solvent flush with propylene glycol followed by a filtered rinse validation because residual glycerol formal can plasticize downstream gaskets.

When the same active ingredient is transferred to an ovine oral drench, the critical deviation from injectable manufacture is no longer sterility but pH-solubility stability and preservative efficacy across repeated container opening. The target concentration is 0.08–0.10% w/v (0.8–1.0 mg/mL) abamectin as avermectin B1a; the exact strength is fixed by the authorized product file and target species, with the lower end used where lambs are drenched at 1 mL/10 kg bodyweight. The water-miscible vehicle uses a polar cosolvent such as N-methyl-2-pyrrolidone or propylene glycol, buffered to pH 4.5–5.5 with a citrate or acetate system, because alkaline hydrolysis of the macrocyclic lactone accelerates above pH 6.5 and reduces B1a recovery below the shelf-life limit. Sodium benzoate is included at 0.1–0.2% w/w and the solution is brought to final volume with purified water before a 20 µm nylon polish filtration.

Production lines for this drench are stainless-steel mixing skids with a high-shear disperser run at 600–1,200 rpm after the cosolvent premix is added; the vessel is not nitrogen-blanketed, but dissolved oxygen is controlled below 1 mg/L by vacuum deaeration to protect the B1a fraction. Terminal packs are 1 L, 2.5 L, and 5 L flexible laminate or HDPE drench packs, filled by volumetric piston pumps with a ±1.0% target stroke calibration. Release includes pH per Ph. Eur. 2.2.3, density per Ph. Eur. 2.2.5, microbial enumeration per Ph. Eur. 5.1.4, antimicrobial preservative effectiveness per Ph. Eur. 5.1.3, and assay of B1a and B1b by HPLC. The bioequivalence file for a generic ovine drench follows VICH GL52; the comparator is the reference oral solution in the target market. The operational boundary for field storage is freezing below −5°C, which can produce a reversible precipitate that does not redissolve uniformly in a partially thawed pack; thawed product must be discarded if phase separation persists after 24 h at 20°C with gentle inversion.

When Feed Meal Is Replaced by Pelleted Granules

Feed premix and granule production for porcine nematode control shifts the process risk from dissolution chemistry to segregation and thermal history. Abamectin crystals have poor flow and high electrostatic charging; when released from a screw feeder into a ribbon blender at 60–70% fill level, the coefficient of variation for assay can exceed 15% if the API is added undiluted. The standard approach starts with a milled premix concentrate at 1.0–3.0% w/w abamectin on a fine lactose or corncob carrier, prepared in a 300–600 kg double-helical ribbon blender. The concentrate is then diluted in a second blending stage to the registered final feed concentration, typically below 0.1% w/w in complete feed; exact levels are set by national antiparasitic authorization and are adjusted to bodyweight-dependent feed intake. If the same line is used for sulfonamides or ionophores, flush with ground corn and validate carryover below 1% of the lowest therapeutic dose before releasing the next product.

Where the medicated feed is pelleted, the post-conditioning line must not expose abamectin to sustained heat. The conditioner is run at <65°C with 20–30 s retention, and the pellet die compression ratio is held between 1:8 and 1:10; elevated compressional heating in a worn die can push product temperature past 70°C and accelerate B1a loss. Batch homogeneity is verified by sampling according to ISO 6497:2002 with a release limit of across-batch coefficient of variation <5%, and carryover validation is conducted under Regulation (EU) 2019/4; the feed hygiene baseline is Regulation (EC) No 183/2005. Terminal formats are 1 kg, 5 kg, and 25 kg multi-wall paper bags with an inner polyethylene liner; moisture is held below 5% w/w and water activity below 0.6 to prevent caking and microbial growth. The operating boundary is in-feed stability: published data for long-term stability in high-mineral porcine feeds is limited, so a site-specific stability study should bracket two dietary calcium levels and two premix inclusion ratios before launch.

In companion animal tablet and capsule manufacturing, the primary process limit is uniformity of dosage units when the active ingredient constitutes a very small mass fraction of the core. Tablet strengths are compressed between 2.5 mg and 10 mg abamectin per unit, with content per core from 1.0% w/w to 5.0% w/w depending on dose and filler system; above 5.0% w/w, the hydrophobic API lowers compactibility and produces edge picking on the tablet tooling, while below 1.0% w/w, the blend is sensitive to demixing in hoppers. A wet-granulation route using pregelatinized starch, microcrystalline cellulose, and crospovidone is preferred over direct compression because it binds the needle-like API onto carrier particles and reduces dust generation during die filling.

Drying is performed in a fluid-bed dryer with inlet air temperature 50–60°C and product temperature maintained below 40°C; loss on drying is released at <2.5% w/w because abamectin in the presence of residual water and acid excipients undergoes hydrolysis during storage. Compression is run on a rotary press with pre-compression to prevent lamination; tablet breaking force is controlled at 40–80 N and friability is held below 1.0% per USP <1216>. Capsule formats are filled on tamping-pin or dosator machines, with content uniformity per USP <905> and dissolution per USP <711> using a validated surfactant medium because the active ingredient is practically insoluble in water. Terminal packaging is PVC/PVDC or PVC/PE/PVdC aluminum blister for tablets and HDPE bottles with an induction-sealed liner for capsules. The label must carry the MDR1 boundary: abamectin at therapeutic doses crosses the blood-brain barrier in P-glycoprotein-defective collie-type dogs, so tablet and capsule formulations are restricted to breeds and species expressly cleared by the approved product file. Published data for this specific configuration is limited in cats; extrapolation from canine data is not permitted.

Water-Dispersible Powder Aqueous Dispersion and Proportioner Line Pressure

For drinking-water medication, abamectin crystals do not remain suspended after simple blending because the native solid has a high contact angle and low aqueous wetting. The downstream powder format is therefore a spray-dried solid dispersion on a carrier of maltodextrin and a non-ionic block copolymer; the final powder carries 1.0% w/w abamectin as avermectin B1a and is designed to wet within 60 s when added to water at 1 g/L at 20°C. Spray drying is run with inlet air 140–160°C, outlet air 65–75°C, and a rotary atomizer; the outlet temperature is the critical limit because abamectin remains amorphous in the dispersion and can recrystallize into slow-dissolving needles if the outlet exceeds 75°C. The milled powder is controlled to a particle size D90 <150 µm by ISO 13320:2020 or Ph. Eur. 2.9.31; moisture is released below 3.0% w/w and packed with desiccant to maintain the amorphous state.

On-farm proportioners for this powder operate between 2 bar and 5 bar line pressure; when water hardness exceeds 250 mg/L calcium carbonate, the non-ionic dispersant can lose effectiveness and the product may flocculate, causing proportioner dosing pumps to drift by more than 10% from the target medication rate. Terminal packages are 100 g, 500 g, and 1 kg PET bottles with induction liners, or foil-laminated sachets for humid climates. Quality-release includes dispersibility under a standardized stir test, loss on drying per USP <731>, assay of B1a and B1b by HPLC, and microbial enumeration per Ph. Eur. 2.6.12 and 2.6.13. The operational boundary is that stock solutions should not be prepared more than 6 h before use if the water temperature exceeds 25°C, because extended contact with municipal chlorine above 1 mg/L can oxidize the macrocyclic lactone and reduce potency at the drinking point.